발열성 호중구 감소증 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The Febrile Neutropenia Market Size is anticipated to grow with a significnat CAGR during the study period (2022-2036).
• The leading Febrile Neutropenia companies developing therapies include - Amneal Pharmaceuticals, Inc., AstraZeneca, Aurobindo Pharma Limited, Bayer, BeyondSpring Inc., Biocon Biologics Ltd., Biogen, Bristol Myers Squibb, Celgene, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Eli Lilly and Company, Fresenius Kabi, G1 Therapeutics, Inc., Gedeon Richter Plc., GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Partner Therapeutics, Inc., Pfizer Inc., Roche, Sanofi, Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and others.

Febrile Neutropenia Market and Epidemiology Analysis

• Febrile neutropenia, also known as neutropenic fever, is the most frequent and serious complication associated with cancer treatment.
• Neutropenic fever is characterized by either a one-time oral temperature of 101°F (38.3°C) or higher, or a sustained temperature of at least 100.4°F (38°C) for one hour or more, accompanied by an absolute neutrophil count (ANC) below 1500 cells per microliter.
• The Febrile Neutropenia market is projected to grow steadily from 2025 to 2034, driven by the rising global cancer burden, increased use of myelosuppressive chemotherapy, and growing awareness of infection risks in immunocompromised patients. Advancements in prophylactic antimicrobials, granulocyte-colony stimulating factor (G-CSF) therapies, and improved risk stratification approaches-alongside a robust clinical research pipeline-are expected to support continued market expansion and enhance patient outcomes.
• The approvals of ROLVEDON and RYZNEUTA represent important progress in granulocyte colony-stimulating factor (G-CSF) therapies for febrile neutropenia, providing long-acting, patient-centered options that improve infection prevention and help maintain continuity of cancer treatment.
• The febrile neutropenia pipeline remains relatively limited, reflecting ongoing reliance on supportive care over innovative therapies. Most progress centers on optimizing existing granulocyte colony-stimulating factors, with few novel or targeted agents emerging. This highlights a significant unmet need for differentiated treatments, especially for high-risk or treatment-refractory patients.
• Market growth in febrile neutropenia is primarily fueled by rising cancer incidence and widespread chemotherapy use. Advancements in supportive care-including novel antimicrobials, growth factors-and improved diagnostics and personalized strategies are enhancing treatment. However, the growing challenge of antimicrobial resistance continues to complicate effective management.

Factors impacting the Febrile Neutropenia Market Growth

Rising Incidence of Cancer

The global increase in cancer cases significantly drives the febrile neutropenia market, as a large proportion of patients undergoing chemotherapy experience neutropenia and are at high risk of infection.

Increased Use of Myelosuppressive Therapies

The expanding use of chemotherapy, targeted therapies, and combination regimens in oncology increases the likelihood of neutropenia, creating sustained demand for febrile neutropenia prevention and management solutions.

Growing Adoption of Prophylactic Treatments

Wider use of granulocyte-colony stimulating factors (G-CSFs) for prevention has reduced complications and improved patient outcomes, strengthening market growth across treatment and supportive care settings.

Expansion of Biosimilars

The availability of biosimilar G-CSFs has improved treatment affordability and accessibility, particularly in cost-sensitive markets, encouraging broader adoption.

Improved Healthcare Infrastructure

Advancements in healthcare facilities, oncology support services, and access to diagnostics have enhanced the ability to diagnose and manage febrile neutropenia effectively.

DelveInsight's comprehensive report titled "Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast - 2036" offers a detailed analysis of febrile neutropenia. The report presents historical and projected epidemiological data covering total incident cases of Febrile Neutropenia, etiology-specific cases of Febrile Neutropenia, severity-specific cases of Febrile Neutropenia, and treated cases of Febrile Neutropenia. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2022 to 2036.

The report analyzes the existing treatment practices and unmet medical requirements in Febrile Neutropenia. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Febrile Neutropenia Disease Understanding

Neutropenic fever is defined as a single oral temperature =101°F (38.3°C) or a sustained temperature =100.4°F (38°C) for over an hour, accompanied by an absolute neutrophil count (ANC) below 1500 cells/µL. It is considered severe when ANC falls below 500/µL and profound when below 100/µL. In many cases, the exact cause of infection remains unidentified, and the fever is classified as fever of unknown origin (FUO).

Neutropenic fever is the most frequent and serious complication in patients with hematologic cancers or those undergoing chemotherapy. It arises when an immunocompromised patient encounters an infection, often due to weakened immune defenses and damaged barriers like the gastrointestinal or sinus mucosa, allowing pathogens to invade.

Febrile Neutropenia Diagnosis:

The diagnosis of febrile neutropenia is primarily based on the presence of fever in a patient with neutropenia, typically defined as a single oral temperature >=38.3°C or a sustained temperature >=38.0°C for over one hour, along with an absolute neutrophil count below 500 cells/µL or expected to fall to this level. Prompt clinical evaluation is essential and includes a thorough history, physical examination, and assessment of risk factors related to recent chemotherapy. Initial investigations usually involve complete blood counts, blood cultures from peripheral and central lines, urine analysis, chest imaging if respiratory symptoms are present, and other site-specific cultures as indicated. Risk stratification tools help classify patients into low- or high-risk categories, guiding subsequent management decisions.

Febrile Neutropenia Treatment:

Treatment of febrile neutropenia is a medical emergency and should begin immediately after cultures are obtained, without waiting for results. Empirical broad-spectrum intravenous antibiotics with coverage against gram-negative organisms are initiated, especially in high-risk patients, while low-risk patients may be managed with oral antibiotics in an outpatient setting. Therapy is adjusted based on clinical response, culture results, and local resistance patterns. Supportive care includes the use of granulocyte-colony stimulating factors in selected patients, management of complications, and close monitoring of vital signs and blood counts. Antibiotic therapy is continued until the patient is afebrile and neutrophil recovery is achieved or an alternative diagnosis is established.

Febrile Neutropenia Epidemiology

The epidemiology section of the febrile neutropenia market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of Febrile Neutropenia. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings from Febrile Neutropenia Epidemiological Analyses and Forecast

• Febrile neutropenia occurs in up to 30% of cancer patients undergoing chemotherapy and approximately 50% of these patients develop an infection, with bacteremia occurring in about 20% of those with profound neutropenia.
• According to Wondm et al. (2025), over half of febrile neutropenia patients (51.9%) had hematologic malignancies, with acute myeloid leukemia (13.6%) and acute lymphoblastic leukemia (12.1%) being the most prevalent, while among solid tumors, cervical cancer (8.1%) was the leading type, followed by breast (7.4%) and ovarian cancer (6.7%) in France.
• As per the study by Yoshinami et al. (2025), among 33,310 early breast cancer patients, febrile neutropenia occurred in 5.73% (1,910 patients), in Japan.

Febrile Neutropenia Market Segmentation

DelveInsight's 'Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast - 2036' report provides a detailed outlook of the current and future febrile neutropenia market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Febrile Neutropenia Market Size by Countries

The febrile neutropenia market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the United States held a significant share of the overall 7MM (Seven Major Markets) febrile neutropenia market, primarily attributed to the country's higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Febrile Neutropenia Market Size by Therapies

Febrile Neutropenia Market Size by Therapies is categorized into current and emerging markets for the study period 2022-2036.

Febrile Neutropenia Drug Analysis

Febrile Neutropenia Marketed Drugs

ROLVEDON (eflapegrastim-xnst): Assertio Holdings/Spectrum Pharmaceuticals

ROLVEDON (eflapegrastim-xnst) is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation. Spectrum has received an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

• In September 2022, Spectrum Pharmaceuticals, announced that the US FDA has approved ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
• In July 2023, Assertio Holdings has announced the completion of its planned acquisition of Spectrum Pharmaceuticals.

RYZNEUTA (efbemalenograstim alfa-vuxw): Evive Biotechnology/Acrotech Biopharma

RYZNEUTA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. RYZNEUTA is the first non-pegylated granulocyte colony-stimulating factor approved by both the US FDA.

• In November 2023, Evive Biotech and Acrotech Biopharma announced that the US FDA has approved RYZNEUTA (efbemalenograstim alfa) for the reduction of infection risk, as indicated by febrile neutropenia, in adult patients with non-myeloid cancers undergoing myelosuppressive chemotherapy associated with a clinically significant risk of febrile neutropenia.
• In March 2024, Evive Biotech announced European Commission approval of RYZNEUTA (efbemalenograstim alfa injection) for chemotherapy-induced neutropenia (CIN).

Febrile Neutropenia Emerging Drugs

Plinabulin: BeyondSpring

Plinabulin is a first-in-class, small-molecule selective immunomodulating microtubule-binding agent (SIMBA) that exerts both anti-cancer and hematopoietic protective effects. Unlike traditional G-CSFs, plinabulin works through a differentiated mechanism by promoting dendritic cell maturation, modulating immune response, and protecting hematopoietic stem/progenitor cells from chemotherapy-induced damage, thereby reducing the incidence of febrile neutropenia.

The drug has been primarily investigated for the prevention of chemotherapy-induced neutropenia in combination with G-CSF, demonstrating clinical benefit in reducing the duration of severe neutropenia and improving immune recovery in patients receiving myelosuppressive chemotherapy. The drug has received Breakthrough Therapy Designation (BTD) for the chemotherapy-induced neutropenia indication from the US FDA.

Plinabulin has completed Phase III clinical development; however, in 2022, the US FDA issued a Complete Response Letter (CRL) citing the need for additional clinical data, particularly to confirm clinical benefit in reducing febrile neutropenia risk. As a result, its regulatory approval has been delayed. As of now, there have been no publicly available major regulatory or clinical updates reported post-2022.

AKT-011: Akthelia Pharmaceuticals

AKT-011, is a first-in-class, orally administered small-molecule immunomodulator currently in preclinical development for the prevention of febrile neutropenia. The drug is designed to act locally in the gastrointestinal tract by enhancing epithelial barrier integrity and upregulating innate immune defense mechanisms, thereby preventing bacterial translocation, a key driver of infection and sepsis in neutropenic patients.

As per company's 2023 pipeline, the candidate is advancing through preclinical stages up to IND-enabling activities, with Phase I expected to begin around 2024, followed by subsequent clinical development for febrile neutropenia; however, no recent updates are currently available.

Febrile Neutropenia Market Outlook

The febrile neutropenia therapeutics market is further expected to increase by the major drivers, such as the rising incidence population, technological advancements, and upcoming therapies in the forecast period (2026-2036).With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Febrile Neutropenia market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Febrile Neutropenia Competitive Landscape

The competitive landscape of the febrile neutropenia market is characterized by the presence of established pharmaceutical companies focused on supportive oncology care, particularly in the development and commercialization of granulocyte-colony stimulating factors and anti-infective therapies. Market competition is driven by branded biologics and a growing number of biosimilars that enhance treatment affordability and expand patient access. Companies compete on factors such as product efficacy, safety profiles, dosing convenience, pricing strategies, and geographic reach. Ongoing innovation, lifecycle management of existing therapies, strategic collaborations, and expansion into emerging markets continue to shape competition, while increasing emphasis on preventive care and outpatient management further influences market positioning.

Key Febrile Neutropenia Companies

The leading Febrile Neutropenia companies developing therapies include -

• Amneal Pharmaceuticals, Inc.,
• AstraZeneca,
• Aurobindo Pharma Limited,
• Bayer,
• BeyondSpring Inc.,
• Biocon Biologics Ltd.,
• Biogen, Bristol Myers Squibb,
• Celgene, Cellerant Therapeutics, Inc.,
• Coherus BioSciences, Inc.,
• Eli Lilly and Company,
• Fresenius Kabi,
• G1 Therapeutics, Inc.,
• Gedeon Richter Plc.,
• GlaxoSmithKline,
• Hanmi Pharmaceutical Co., Ltd.,
• Intas Pharmaceuticals Ltd.,
• Johnson & Johnson,
• Kyowa Kirin Co., Ltd.,
• Merck & Co., Inc.,
• Novartis AG,
• Partner Therapeutics, Inc.,
• Pfizer Inc.,
• Roche,
• Sanofi,
• Spectrum Pharmaceuticals, Inc.,
• Teva Pharmaceutical Industries Ltd.,
• Viatris Inc., and others.

Febrile Neutropenia Drugs Uptake

This section focuses on the sales uptake of potential febrile neutropenia drugs that have recently been launched or are anticipated to be launched in the febrile neutropenia market between 2022 and 2036. It estimates the market penetration of febrile neutropenia drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the febrile neutropenia market.The emerging febrile neutropenia therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Febrile Neutropenia market.

Febrile Neutropenia Clinical Trials Analysis

The Febrile Neutropenia pipeline report offers an analysis of Febrile Neutropenia clinical trials within Phase II and III stages and examines companies involved in developing targeted therapeutics for febrile neutropenia. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Febrile Neutropenia Pipeline Development Activities

The Febrile Neutropenia clinical trials analysis report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging febrile neutropenia therapies.

Febrile Neutropenia Market Access and Reimbursement

DelveInsight's 'Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of febrile neutropenia.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Latest KOL Views on Febrile Neutropenia

To keep up with current febrile neutropenia market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the febrile neutropenia domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or febrile neutropenia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the febrile neutropenia unmet needs.

Febrile Neutropenia Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the febrile neutropenia market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Febrile Neutropenia Market Report Insights

• Febrile Neutropenia Patient Population
• Febrile Neutropenia Therapeutic Approaches
• Febrile Neutropenia Pipeline Analysis
• Febrile Neutropenia Market Size and Trends
• Febrile Neutropenia Market Opportunities
• Impact of Upcoming Febrile Neutropenia Therapies

Febrile Neutropenia Market Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Febrile Neutropenia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Febrile Neutropenia Market
• Febrile Neutropenia Drugs Uptake

Febrile Neutropenia Market Report Assessment

• Febrile Neutropenia Current Treatment Practices
• Febrile Neutropenia Unmet Needs
• Febrile Neutropenia Pipeline Product Profiles
• Febrile Neutropenia Market Attractiveness
• Febrile Neutropenia Market Drivers
• Febrile Neutropenia Market Barriers

Key Questions Answered In The Febrile Neutropenia Market Report:

• How common is febrile neutropenia?
• What are the key findings of febrile neutropenia epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022-2036)?
• What are the currently available treatments for febrile neutropenia?
• What are the disease risk, burden, and unmet needs of febrile neutropenia?
• At what CAGR is the febrile neutropenia market and its epidemiology is expected to grow in the 7MM during the forecast period (2026-2036)?
• How would the unmet needs impact the febrile neutropenia market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of febrile neutropenia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2026-2036)?
• How many companies are currently developing therapies for the treatment of febrile neutropenia?

Reasons to buy Febrile Neutropenia Market Forecast Report

• The Febrile Neutropenia report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the febrile neutropenia Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the Febrile Neutropenia unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for febrile neutropenia?

The primary goals in treating febrile neutropenia are to promptly control infection, restore neutrophil counts, and prevent complications like sepsis. Management involves early broad-spectrum antibiotics, fever resolution, and immune stabilization to reduce morbidity and hospital stay. Long-term strategies include prophylactic antimicrobials, G-CSF support, and chemotherapy optimization, with a focus on improving quality of life and reducing recurrence.

2. What are the challenges in managing febrile neutropenia?

Managing febrile neutropenia is challenging due to its rapid onset, varied infectious etiologies, and the immunocompromised state of patients. Diagnosis is complicated by nonspecific symptoms and difficulty in identifying the infection source. Long-term management is hindered by chemotherapy-induced bone marrow suppression, rising antimicrobial resistance, and limited access to supportive treatments like G-CSF. Financial burden, poor adherence, and comorbidities further complicate sustained infection control.

3. What are the key factors driving the growth of the febrile neutropenia market?

Key factors driving the growth of the febrile neutropenia market include rising cancer rates, broader use of myelosuppressive chemotherapy, and heightened awareness of infection risks. Advances in long-acting G-CSF, rapid diagnostics, and the availability of biosimilars have improved prevention and access. Increased healthcare investment and favorable reimbursement are also fueling market growth.

4. How will the Febrile Neutropenia Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current febrile neutropenia market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.

Table of Contents

1 Key Insights

2 Report Introduction

3 Market Overview at a Glance

• 3.1. Market Share (%) Distribution by Therapies in 2025
• 3.2. Market Share (%) Distribution by Therapies in 2036

4 Epidemiology and Market Methodology

5 Executive Summary

6 Key Events

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Types
• 7.3 Causes
• 7.4 Pathophysiology
• 7.5 Symptoms
• 7.6 Risk Factor
• 7.7 Diagnosis
  • 7.7.1 Diagnostic Algorithm
  • 7.7.2 Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1 Treatment Algorithm
  • 7.8.2 Treatment Guidelines

8 Febrile Neutropenia Epidemiology and Patient Population

• 8.1 Key Findings
• 8.2 Assumptions and Rationale: The 7MM
• 8.3 Total Incident Cases of Febrile Neutropenia in the 7MM
• 8.4 The US
  • 8.4.1 Total Incident Cases of Febrile Neutropenia
  • 8.4.2 Etiology-specific Cases of Febrile Neutropenia
  • 8.4.3 Severity-specific Cases of Febrile Neutropenia
  • 8.4.4 Treated Cases of Febrile Neutropenia
• 8.5 EU4 and the UK
  • 8.5.1 Total Incident Cases of Febrile Neutropenia
  • 8.5.2 Etiology-specific Cases of Febrile Neutropenia
  • 8.5.3 Severity-specific Cases of Febrile Neutropenia
  • 8.5.4 Treated Cases of Febrile Neutropenia
• 8.6 Japan
  • 8.6.1 Total Incident Cases of Febrile Neutropenia
  • 8.6.2 Etiology-specific Cases of Febrile Neutropenia
  • 8.6.3 Severity-specific Cases of Febrile Neutropenia
  • 8.6.4 Treated Cases of Febrile Neutropenia

9 Febrile Neutropenia Patient Journey

10 Febrile Neutropenia Marketed Therapies

• 10.1 Key Cross Competition
• 10.2 ROLVEDON (eflapegrastim-xnst): Assertio Holdings/Spectrum Pharmaceuticals
  • 10.2.1 Drug Description
  • 10.2.2 Regulatory Milestones
  • 10.2.3 Other Development Activities
  • 10.2.4 Clinical Trials Information
  • 10.2.5 Safety and Efficacy
• 10.3 RYZNEUTA (efbemalenograstim alfa-vuxw): Evive Biotechnology/Acrotech Biopharma
  • 10.3.1 Drug Description
  • 10.3.2 Regulatory Milestones
  • 10.3.3 Other Development Activities
  • 10.3.4 Clinical Trials Information
  • 10.3.5 Safety and Efficacy

11 Febrile Neutropenia: Seven Major Market Analysis

• 11.1 Key Findings
• 11.2 Key Market Forecast Assumptions
  • 11.2.1 Cost Assumptions and Rebates
  • 11.2.2 Pricing Trends
  • 11.2.3 Analogue Assessment
  • 11.2.4 Launch Year and Therapy Uptake
• 11.3 Market Outlook
• 11.4 Attribute Analysis
• 11.5 Total Market Size of Febrile Neutropenia in the 7MM
• 11.6 Market Size of Febrile Neutropenia by Therapies in the 7MM
• 11.7 The US Market Size
  • 11.7.1 Total Market Size of Febrile Neutropenia
  • 11.7.2 Market Size of Febrile Neutropenia by Therapies
• 11.8 EU4 and the UK Market Size
  • 11.8.1 Total Market Size of Febrile Neutropenia
  • 11.8.2 Market Size of Febrile Neutropenia by Therapies
• 11.9. Japan Market Size
  • 11.9.1 Total Market Size of Febrile Neutropenia
  • 11.9.2 Market Size of Febrile Neutropenia by Therapies

12 Key Opinion Leaders' Views

13 Febrile Neutropenia Unmet Needs

14 SWOT Analysis

15 Febrile Neutropenia Market Access and Reimbursement

• 15.1 United States
  • 15.1.1 Centre for Medicare and Medicaid Services (CMS)
• 15.2 EU4 and the UK
  • 15.2.1 Germany
  • 15.2.2 France
  • 15.2.3 Italy
  • 15.2.4 Spain
  • 15.2.5 United Kingdom
• 15.3 Japan
  • 15.3.1 MHLW

16 Appendix

• 16.1 Bibliography
• 16.2 Abbreviations and Acronyms
• 16.3 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight